Immunic (IMUX) Earnings Date & Reports

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

IMUX is expected to report earnings to fall 24.76% to -18 cents per share on August 07

Q2'25

Est.

$-0.19

Q1'25

Missed

by $0.03

Q4'24

Missed

by $0.01

Q3'24

Missed

by $0.02

Q2'24

Beat

by $0.02

The last earnings report on May 08 showed earnings per share of -25 cents, missing the estimate of -22 cents. With 14.44M shares outstanding, the current market capitalization sits at 73.23M.

View a ticker or compare two or three

Compare

IMUX